Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen G Ellis

Showing results (241-250 of 252) with videos related to

Pageof 26
Sort By:
Circulation Research|November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trialRobert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Cell Transplantation|November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN TrialDoris A Taylor, Emerson C Perin, James T Willerson, et al.
American Heart Journal|August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and designJames T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal|September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
American Heart Journal|August 25, 2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
Circulation Research|August 20, 2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomesChristopher R Cogle, Elizabeth Wise, Amy M Meacham, et al.
Circulation. Cardiovascular Genetics|February 10, 2012
A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complexRobert W Davies, George A Wells, Alexandre F R Stewart, et al.
JACC. Cardiovascular Interventions|December 9, 2017
The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert PanelSripal Bangalore, Hiram G Bezerra, David G Rizik, et al.
JAMA|March 27, 2012
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trialEmerson C Perin, James T Willerson, Carl J Pepine, et al.
JAMA|November 7, 2012
Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trialJay H Traverse, Timothy D Henry, Carl J Pepine, et al.
Pageof 26

Showing results (241-250 of 252) with videos related to

Sort By:
Pageof 26
Circulation Research|November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trialRobert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Cell Transplantation|November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN TrialDoris A Taylor, Emerson C Perin, James T Willerson, et al.
American Heart Journal|August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and designJames T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal|September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
American Heart Journal|August 25, 2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
Circulation Research|August 20, 2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomesChristopher R Cogle, Elizabeth Wise, Amy M Meacham, et al.
Circulation. Cardiovascular Genetics|February 10, 2012
A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complexRobert W Davies, George A Wells, Alexandre F R Stewart, et al.
JACC. Cardiovascular Interventions|December 9, 2017
The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert PanelSripal Bangalore, Hiram G Bezerra, David G Rizik, et al.
JAMA|March 27, 2012
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trialEmerson C Perin, James T Willerson, Carl J Pepine, et al.
JAMA|November 7, 2012
Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trialJay H Traverse, Timothy D Henry, Carl J Pepine, et al.
Pageof 26